Dr. Steve Caffé

Dr. Steve Caffé brings to CRISPR Therapeutics a 25-year track record in global product development and regulatory affairs, having held senior leadership positions at several leading biotechnology and pharmaceutical companies. During his career, Steve has demonstrated exceptional leadership in global regulatory affairs and patient safety. He has contributed to over 40 new drug approvals and major new indications worldwide in a wide range of therapeutic areas, including oncology, hematology, cardiology and rare diseases. Prior to joining our company, Steve served as Senior Vice President at Ra Pharmaceuticals, where he led Regulatory Affairs, Pharmacovigilance, Quality and Patient Advocacy. Before that, he held senior level regulatory positions at a number of publicly traded biopharmaceutical companies including Sucampo Pharmaceuticals, AMAG Pharmaceuticals, MedImmune (Biologics Division of AstraZeneca), Baxter, Sanofi-Aventis and Merck. Steve received his M.D. at the Université Pierre et Marie Curie in Paris, France.

Previous Next